Research

Hormonal

Direct activation of GLP-1 receptors in the ventral tegmental area (VTA) and nucleus accumbens (NAc) core reduces the intake of highly-palatable foods (sucrose and high-fat diet) and body weight, mediated by direct projections from NTS GLP-1 neurons.

This research suggests that GLP-1 medications (like semaglutide or liraglutide) work partly by targeting the brain's reward system (VTA and Nucleus Accumbens) rather than just signaling fullness to the stomach. By dampening the reward signal associated with highly palatable, high-fat, or sugary foods, these drugs reduce the motivation to eat them. This explains why users often find themselves losing interest in junk food specifically, rather than just feeling physically stuffed.

GoodSupportsHIGH confidence
Pharmacological data showed that GLP-1R activation in the VTA, NAc core, and NAc shell decreased food intake, especially of highly-palatable foods, and body weight.
Amber L. Alhadeff et al. · Endocrinology · 2011

Why this rating

High-quality animal study with rigorous anatomical tracing (Fluorogold) and pharmacological validation (agonist/antagonist), though results are specific to rats.

Source

GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake

Amber L. Alhadeff et al. · Endocrinology · 2011

DOI 10.1210/en.2011-1443

mechanism_onlyCited 476×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →